Reply to: Enfortumab Vedotin: A Promising Therapy for Head and Neck Cancer With Potential Links to Human Papillomavirus

Paul L. Swiecicki

Emrullah Yilmaz

Johnson & Johnson, Raritan, NJ

Ari Joseph Rosenberg

Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, IL

Takao Fujisawa

Justine Yang Bruce

University of Wisconsin Carbone Cancer Center, Madison, WI

Changting Meng

Pfizer, Bothell, WA

Michele Wozniak

Paul L. Swiecicki, MDDepartment of Internal Medicine, Division of Hematology/Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, Emrullah Yilmaz, MD, PhD, Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, Ari Joseph Rosenberg, MDDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, Takao Fujisawa, MD, Head and Neck Medical Oncology, National Cancer Center Hospital East, Chiba, Japan, Justine Bruce, Yang MD, University of Wisconsin Carbone Cancer Center, Madison, WI, Changting Meng, MD, Pfizer, Bothell, WA, Michele, Wozniak PhD, Yongyun Zhao, PhD, Michael Mihm, PhD, Jason Kaplan, MD, and Seema Gorla, MD Astellas Pharma, Inc, Northbrook, IL and Jessica L. Geiger MD, Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

Yongyun Zhao

National Engineering Laboratory for Druggable Gene and Protein Screening, College of Life Science, Northeast Normal University

Michael Mihm

Astellas Pharma, Northbrook, IL

Jason Kaplan

Paul L. Swiecicki, MDDepartment of Internal Medicine, Division of Hematology/Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, Emrullah Yilmaz, MD, PhD, Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, Ari Joseph Rosenberg, MDDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, Takao Fujisawa, MD, Head and Neck Medical Oncology, National Cancer Center Hospital East, Chiba, Japan, Justine Bruce, Yang MD, University of Wisconsin Carbone Cancer Center, Madison, WI, Changting Meng, MD, Pfizer, Bothell, WA, Michele, Wozniak PhD, Yongyun Zhao, PhD, Michael Mihm, PhD, Jason Kaplan, MD, and Seema Gorla, MD Astellas Pharma, Inc, Northbrook, IL and Jessica L. Geiger MD, Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

Seema Gorla

Paul L. Swiecicki, MDDepartment of Internal Medicine, Division of Hematology/Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, Emrullah Yilmaz, MD, PhD, Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, Ari Joseph Rosenberg, MDDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, Takao Fujisawa, MD, Head and Neck Medical Oncology, National Cancer Center Hospital East, Chiba, Japan, Justine Bruce, Yang MD, University of Wisconsin Carbone Cancer Center, Madison, WI, Changting Meng, MD, Pfizer, Bothell, WA, Michele, Wozniak PhD, Yongyun Zhao, PhD, Michael Mihm, PhD, Jason Kaplan, MD, and Seema Gorla, MD Astellas Pharma, Inc, Northbrook, IL and Jessica L. Geiger MD, Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

Jessica L. Geiger

Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH